INTRODUCTION
Osteosarcoma (OS) is the most frequent primary bone malignancy with an annual incidence of around 3 cases per million in Europe, which is higher in adolescents (0.8-1.1/100,000/year for ages 15--19) 1 . The survival rates for OS patients increased dramatically with the introduction of chemotherapy but have since reached a plateau. Treatment consists of neoadjuvant chemotherapy followed by surgical resection and adjuvant chemotherapy 2 . Today, 5-year overall survival rates for patients with localized disease are up to 70--75%, but this drops to 20--30% for those with metastatic disease 3 .
Whole genome sequencing of high-grade OS has confirmed that these cancers demonstrate significant chromosomal instability with high levels of somatic structural variations and copy number alterations 4, 5 . In addition, cancers with higher mutational loads and tumor-specific neoantigens have been associated with a higher level of immune infiltration 6 . To date, the search for common molecular therapeutic targets in OS has been disappointing. Several pathways have been targeted in clinical trials with varying results but ultimately no significant improved outcome (for review see 7 ) .
The OS bone microenvironment is heterogeneous and consists of osteoclasts, osteoblasts and hematopoietic cells from which monocytes/macrophages derive. All of these cells release multiple growth factors and cytokines with contrasting effects that are not well documented in the context of OS. However it is widely thought that this microenvironment plays an important role in tumor development. Indeed, intratumoral accumulation of Forkhead box P3 (FOXP3 + ) regulatory T-cells has been shown as a major immune escape mechanism of many tumors. In osteosarcomas, the ratio of intratumoral CD8 + T-cells to FOXP3 + cells in pretreatment biopsies was able to separate OS patients with prolonged survival from non-survivors 8 . A recent study reported that the immune infiltrate in OS is mainly composed of tumor-associated macrophages (TAMs), but with a significant number of dendritic cells (DC), T lymphocytes and myeloid cells (MC) 9 . As for most other tumors, tumor infiltration by antigen presenting cells (APCs) including CD1a DCs and CD68 macrophages has been correlated with poorer prognosis, and tumor PDL-1 expression has been associated with a poorer 5- year event-free survival (EFS) 10 .However, other studies have also associated TAMs with reduced metastasis and improved survival in high-grade OS 11, 12 .
Zoledronic acid (ZA) is a bisphosphonate that exerts a direct antiproliferative effect on OS cell lines, reduces primary tumor growth, suppresses lung metastases, and prolongs survival in preclinical studies 13, 14 . Thus, ZA was tested in combination with chemotherapy and surgery for OS patients in France in a randomized phase 3 study (OS2006). The trial was stopped for futility since, unexpectedly, the risk of treatment failure was not reduced and was even marginally higher in ZAtreated (Z+) compared to ZA non-treated (Z-) patients, with the results shown to be stable from sensitivity analyses and fairly homogeneous across the randomization strata 15 . Here we try to explain this lack of effects through the immunohistochemical analysis of the OS-infiltrating immune cells (T lymphocytes, macrophages) in 124 biopsies of patients enrolled in the OS2006 trial. To characterize the macrophage polarization in situ, we stained for the transcription factor pSTAT1 (to indicate T helper 1 responses and M1 polarization) and CMAF (for T helper 2 responses and M2 polarization) 16 .
Our data provide important findings on the OS tumor microenvironment and show that CD163positive M2-polarized macrophages and CD8-positive lymphocytes are strong biomarkers for the therapeutic stratification of OS patients at diagnosis. The demographic, clinical and histological data of the 124 patients compared to the eligible patients population are summarized in Table 1 . They all had biopsies for diagnosis followed by preoperative chemotherapy, then surgery of the primary tumor and post-operative chemotherapy adapted to risk factors, as described in the OS2006 protocol 15 . There were more chondroblastic samples in our study than in the excluded OS2006 population, and more patients treated with the MTX-based chemotherapy. Forty-four (35.5%) of these 124 patients were also randomly selected to receive ZA (Z+) and the other 80 received only chemotherapy (Z- Nanterre, France; clone E1L3N) for 20 minutes at 37°C. Stainings were performed with the Envision kit (DAKO, Carpinteria, CA, USA). Sections were revealed by incubation in a diaminobenzidine solution for 10 minutes then staining with hematoxylin for 5 minutes.
MATERIALS AND METHODS

Patient and tumor characteristics
Immunoreactivity was considered positive if detected in >1% of cells per core of 1mm, irrespective of staining intensity. Anti-CD68 and -CD163 were used to identify macrophages in tissue sections. Their staining was considered "high" when >50% positive cells per core were present. The macrophage polarization was determined in situ by pSTAT1 and CMAF staining respectively for the characterization of M1 and M2 subpopulations. Osteoclastic cells (also known as giant cells) were evaluated independently as giant multinucleated cells by CD68 staining. The presence of CD8 (lymphocyte) checkpoint markers was analyzed with PD1 and PDL-1 antibodies. Tonsils and lymphoid nodes were used as positive controls for the CD8, PD1 and PDL-1 antibodies, giant cell tumors for the CD68 and CD163 antibodies, and lymphoma samples were used for pSTAT1 and CMAF antibodies.
Statistical analysis
Data are summarized as the frequency and percentage for categorical variables and the median and range for continuous variables. Correlations between quantitative data were assessed using the Spearman's rank correlation coefficient. Links with diagnosis status or histological response were assessed with the Fisher's test for categorical covariates and the Mann-Whitney U test for quantitative covariates.
Overall Survival was defined as the time from inclusion to death from any cause (event) or the last follow-up (censored data). Metastatic progression-free survival (MPFS) was defined as the time from inclusion to metastatic progression or death (event) or the last follow-up (censored data).
Patients who locally relapsed as their first event were considered to be censored data, in order to avoid the bias related to the quality of the surgical resection margins. All survival rates were estimated by the Kaplan-Meier method with 95% confidence intervals (CI 
RESULTS
Immunohistochemical analyses
Patient biopsies were subjected to IHC biomarker analysis. The percentage of cells stained for all the markers studied are summarized in Table 2 . Among patients for whom CD163 and CD68 stainings were available, 42/96 (43.8%) and 26/111 (23.4%) had staining greater than 50% per core respectively (Table 2A and Figure 1A and B). To better define macrophage polarization between the M1 and M2 subtypes, the expression of pSTAT1 and CMAF was also tested, showing that high level of CD163 staining was associated with a high level of CMAF nuclear expression but not related to high pSTAT1 expression ( Figure 1C and D).
Forty-three OS samples (38.7%) contained osteoclastic cells. CD8 staining was positive in 58/109 (53.2%) cases but with a low median (1%). PD1 and PDL-1 staining had comparable results, with medians of 0 and no staining in more than 80% of cases (Table 2A and Figure 1E , F, G). Eightyseven of 124 patients presented a double CD163/CD8 staining (70%). Among them, high CD163 > 50% and CD8 > 1% staining was observed in 25 cases (28.7%) (Data not shown).
Statistical analyses
Correlation between biological markers
Correlations between biomarker stainings are presented in presence of osteoclastic cells (median 15 versus 30, for absence vs presence of osteoclastic cells; p = 0.0141) (data not shown).
Biomarkers and clinical parameters associated with diagnosis and histological response
Among the biomarkers tested, only CD8 was associated with the presence of metastases at diagnosis ( Table 3) . Patients with metastases presented a lower CD8 expression (median: 0; range: 0--5) compared to patients with localized disease (median: 1, 0--60; p = 0.0422). The combination of high CD163/CD8 staining was not correlated to the presence of metastases at diagnosis whatever the group of patients (Z+ or Z-). No statistical correlation was found between immunohistochemical parameters and response to chemotherapy (data not shown).
Clinical parameters and biomarkers associated with survival in global population
Univariate and multivariate analysis results are presented in poor response to chemotherapy), a high (>50%) level of CD163-positive cells in biopsies was significantly correlated with a higher overall survival rate in univariate analysis (p = 0.0025, Figure   2 ). A trend for a higher survival was also observed for patients with >50% CD68-positive cells (p = 0.0582; Figure 2 ). Multivariate analysis showed that a high level of CD163 staining was the only significant prognostic factor in addition to the presence of metastases at diagnosis (p = 0.0025; Table   4 ).
Metastatic progression-free survival
Post-treatment events occurred in 37.1% of patients (46/124) and the five-year metastatic progression-free survival (MPFS) rate was estimated to be 61.23% (95%CI [51.58; 69.53]).
Univariate analysis showed that high level of CD163 staining correlated with better MPFS (p = 0.0315) as metastasis at diagnosis and chondroblastic subtype (Table 4; Figure 2 ). After backward selection, only CD163 remains statistically associated with MPFS (p = 0.019) (table 4) .
Correlations between ZA treatment, immunostaining analysis and patient survival
In the group of patients who did not received ZA (Z-), CD163 staining was correlated with overall survival (p = 0.0079), whereas in the group of patients treated with ZA, there was no statistical correlation between CD163 staining and survival (p = 0.1294; Table 5 ). On the contrary, the presence of CD8 significantly correlated with a better overall survival in the group of patients treated with ZA (p = 0.0415; Table 5 and Figure 3 ). However, no significant correlation was found between high levels of the CD163/CD8 double staining and overall survival whatever the group of patients (ZA+ or ZA-) (data not shown). No correlation were found between any marker staining and MPFS ( Table 5 ).
Effect of ZA on macrophages/lymphocytes population in resection specimens
We planed to analyze CD163 and CD68 staining in resection specimens, comparing ZA treated versus ZA untreated patients. The usable resection specimens only correspond to poor responders, with a variable proportion of viable cells ranging from 10 to 100% according to the grading of Huvos and Rosen 2 . The CD163 and CD68 staining assessed in 8 cases of poor responder patients confirmed the high heterogeneity between tumors and within the same tumor (Figures 4 and   5 ), but did not allow us to conclude on the effect of ZA on macrophage populations.
Discussion
Over the past two decades the evolution of systemic treatment for OS has been disappointing and survival has not improved despite several clinical trials conducted worldwide 16, 17 . treated with a MTX-based chemotherapy were higher in the analyzed population as compared to the excluded cohort. However, both parameters could not explain the significant results obtained on the positive correlation between a high CD163 staining and overall survival or metastase-free progression survival.
Our results have identified that TAMs were present in the immune infiltrate in a high proportion of biopsies, and that an increased infiltration was associated with a better prognosis, as it has been previously reported 11, 12 . Among all the targets studied, we clearly identified that CD163 staining was the best prognostic biomarker to predict the outcome of OS2006 patients. Furthermore, we showed that the presence of CD68 and CD163 staining were highly correlated together, which suggests that a common subgroup of macrophages may be present. In agreement, our results clearly demonstrate that high levels of CD163 and CD68 were associated with better overall survival and MPFS; however, although this observation was significant for CD163, it was only a trend for CD68, suggesting that some CD68-positive macrophages have an opposite effect to CD163-positive cells.
Differently polarized macrophages are known to coexist in tissues, M1 macrophages displaying a proinflammatory phenotype and tumoricidal activity. M1 macrophages have also been associated with non-metastatic OS 11, 12 , whereas M2 cells are thought to have an anti-inflammatory wound healing phenotype and favor tumor growth. The balance between the Th1-or Th2-predominant immune responses is thought to drive the shift between M1 versus M2 phenotypic macrophages 19 . This classification of macrophages into two distinct subgroups must however be considered with caution since M2 sub-types are also described to include "non M1" macrophages which adopt heterogeneous activation states and play a wide range of roles in immunity. In addition, it has been demonstrated that CD163 is not an M2-specific macrophage biomarker and that CD163 staining in situ can be associated with Th1 responses, proinflammatory and tumoricidal activity 16 . Furthermore, we found CD163 staining to be associated with high CMAF nuclear expression (a macrophage transcription factor associated with the Th2 immune response and M2 macrophage polarization) and low pSTAT1 expression (a transcription factor related to the Th1 immune response and M1-macrophage polarization) across the sample population. Thus, in the context of the bone microenvironment, the Our results also begin to provide insights into the failure of the OS2006 trial. We showed that CD163 was significantly associated with better overall survival and MPFS in patients in the group without ZA, but not in patients treated with ZA. Based on a recent study from Junankar et al suggesting that macrophages could represent the extraskeletal target for bisphosphonates 22 , we propose that ZA could therefore disrupt the positive effects of CD163 infiltration. Therefore, we planed to analyze CD163 and CD68 staining in resection specimens, comparing ZA treated versus ZA untreated patients. Unfortunately this analysis was not informative and was probably not the good method to estimate the effect of the treatment on the infiltrating immune cells. The first limitation was linked to the fact that the usable resection specimens only correspond to poor responders, with a variable proportion of viable cells ranging from 10 to 100% according to the Huvos and Rosen's grading.The second pitfall was the average of the percentage of viable cells that did not reflect the distribution of cells on the histological section: the distinction between viable isolated nodules (of more than 10% of cells) within necrosis areas, and an homogeneous distribution of more than 10% of viable cells on the whole histological section were not possible with this grading..Therefore, we could not conclude on the effect of ZA on macrophage populations. We planned to answer to this question by another approach that consists in measuring the level of inflammatory cytokines relative to immune cells in the blood samples of OS2006 patients, and to complete this work at transcriptomic level, to determine the proportion of immune cell infiltrate both at diagnosis and also at surgery. The lack of association between CD163 and overall survival or MPFS in ZA treated patients may also be explained by a lack of power of the present statistical analysis due to the small number of ZA treated patients analyzed in our study, and should be validated in a larger series of OS patients.
In contrast to CD163, the level of CD8 staining across the patient samples was low with a median staining of 1%, but CD8 cells were detected in more than half of them and their presence was significantly associated with lower rate of metastasis at diagnosis. The use of a 1mm TMA may have underestimated the number of CD8 cells; however, we selected the most cellular areas of the biopsies for TMAs building, and the comparison of the mean of percentages of stained cells per whole slide was similar in the three core samples. This confirms the results of Frizsching et al who showed that osteosarcoma patients with increased intratumoral CD8 T cell infiltration upon diagnosis have better outcomes 8 . Together, this suggests that CD8 T cells play a role in metastasis development in OS. In addition, the presence of CD8 positive cells significantly correlated with improved survival in patients treated with ZA. This could be related to an interaction between T lymphocytes and macrophages in the context of bone tumor microenvironment. One hypothesis is that zoledronate could sensitize osteosarcoma cells to the Vγ9Vδ2 T cell cytotoxicity. Indeed, several studies in other cancer models report that tumor cell sensitivity to Vγ9Vδ2 T lymphocyte-mediated killing is increased by zoledronate 24, 25 . In osteosarcoma, Liu M et al 23 , described that combining the anti-HER-2 monoclonal antibody trastuzumab and ZA significantly increased the cytotoxic potential of Vγ9Vδ2 T cells.
This hypothesis should be verified in a larger cohort in order to activate CD8-TILs using ZA and/or other CD8 TIL-activating drugs.
Finally, we found that more than 80% of samples were negative for PD1/PDL-1 staining: only one case presented a staining >10% for PD1 and 2 had a staining >10% for PDL-1. These cases also had high CD8 staining (>10%), suggesting that infiltrating CD8 T cells might drive PDL-1 upregulation. Our results are concordant with those of the SARC 028 trial: one out of twenty relapsed OS patients responded to pembrolizumab, a PD1 inhibitor, whereas PDL-1 staining was detected in only 7% of 54 OS specimens 26 . The authors also found PDL-1 expression to be significantly associated with a poorer five-year EFS, but we did not found any correlation. Thus, taken together, these observations suggest that the role of the PD1/PDL-1 checkpoint is not predominant in the pathogenesis of OS. Other checkpoint candidates such as indoleamine 2,3-dioxygenase (IDO), which may explain the suppression of antitumor immunity in the tumor environment via CD8 T cells, may be involved 27 .
In conclusion, our results support four main observations: 1) the presence of TAMs ( In view of these data, we propose that a systematic analysis of CD68, CD163, CD8, PD1 and PDL-1 expression could be performed in OS biopsies at diagnosis (immunoscore) in order to stratify patients regarding their tumor microenvironment, and test a further therapeutic strategy targeting these immunological features (see algorithm in Figure 6 ). This innovative approach, using the immune context of the tumor microenvironment for prognosis, could also be extended to other cancers with complex genomic instability.
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